The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis and uterine fibroids , as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. Serves as a strategic partner across Marketing, Field Sales, Market Access, Medical Affairs, Finance, IT, and New Product Commercialization to shape commercial strategy, guide investment decisions, support portfolio and financial planning through robust forecasting, and build scalable analytical capabilities supporting current and future product launches.